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Review Article 
A review on needle free injections 
ABSTRACT 
At present scenario many researchers are working to develop technology that promises to deliver 
the drug in more efficient and less painful way in order to produce the therapeutic effects. 
Needle-free injection systems are novelways to introduce various medicines into patients without 
piercing the skin with a conventional needle. Needle free injection gives very effective injections 
for a wide range of drugs.  Needle free systems are designed to avoid the problems associated 
with conventional needles making them safer, less expensive, and more suitable. Additional 
benefits include very fast injection compared with conventional needles and no needle disposal 
issues. This review intends to throw light on the basic mechanisms by which this technology 
works, different types of technologies available at present and its applications. 
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INTRODUCTION:  
At present scenario, many researchers are working todevelop technology that promises to make 
the administration of medicine more efficient and less painful
1
. There are a variety of problems 
associated with the hypodermic needles used in injections. These include relatively high cost of 
the needles, lack of reusability i.e. needle syringe should be sterilized, additionally; many people 
have a fear of needles or needle-phobia, which causes them to avoid treatment
2
. These 
drawbacks have led to the development of alternative delivery systems to needle injections. 
Needle-free systems are designed to solve these problems making them safer, less expensive, and 
more convenient. In general, needle-free injection technology works by forcing liquid 
medication at high speed through a tiny orifice that is held against the skin. This creates an ultra-
fine stream of high-pressure fluid that penetrates the skin withoutthe use of a needle
3
. 
These systems are novel ways to administer various medicines into patients systemic circulation 
without piercing the skin with a conventional needle. Needle-free injection is a fast, effective 
route of administration
4
. These technologies have been developed for injecting liquid 
formulations, as well as injecting drugs and vaccines in a solid dosage form.  
In 1853, first hypodermic syringes were first developed by French surgeon, Charles Gabriel 
Pravaz, however there are minor changes in technology since last few decades
5
.  
Needle-free systems were first described by Marshall Lockhart in 1936. Then in the early 1940’s 
Higson and others developed high pressure guns using a fine jetof liquid to pierce the skin and 
deposit the drug in underlying tissue
6
. These devices were used extensively to inoculate against 
infectious diseases and were later applied more generally in large scale vaccination program
7
.  
ADVANTAGES
8, 9, 10, 11, 12 
1. No under- or overdosing condition of the drugs.  
2. Useful in case of patients with needle phobia. 
3. It delivers pain-free injection. Preventsskin puncture hazards and its destruction; also does not 
cause problem of bleeding or bruising and minimal skin response.    
4. Improved patient compliance especially in chronic administration of drugs. 
5. No need to visit hospitals / experts for injections, i,e., self-administration is feasible. 
6. No specific disposal requirements. 
7. No risk of cross contamination from needle-stick injury. 
8. Amount of medicine delivered and the depth can be adjusted. 
  
 
9. Vaccines can be delivered in powdered formas well as viscous liquids. 
10. Better drug stability during storage as it is delivered in dry powder form. 
Disadvantages of needle-free injection
13, 14
  
 1. Method is complex and expensive.  
2. All systems are not fitted into one size.  
3. Need for personnel training and maintenance.  
4. It is not applicable for Intravenous route.? 
Structure of skin 
The skin is one of the largest organs in the body in surface areaand weight.  The skin consists of 
two layers: the epidermis and the dermis. Beneath the dermis lies the hypodermis or 
subcutaneous fatty tissue.  
 
Figure 1: Structure of skin 
Epidermis:  
The epidermis, the outermost layer of skin, provides a waterproof barrierand creates our skin 
tone. It forms the waterproof, protective wrap over the body’s surface and is made up of 
stratified squamous epithelium with an underlying basal lamina. There are no blood vessels in  
epidermis, and cells in the deepest layers are nourished by diffusion from blood capillaries 
extending to the upper layers of the dermis
15
.  
Dermis: The dermis, beneath the epidermis, contains tough connective tissue, hair follicles, and 
sweat glands. The dermis is tightly connected to the epidermis by a basement membrane. The 
blood vessels in the dermis provide nourishment and waste removal from itsown cells as well as 
from the stratum basale of the epidermis
16
.  
Hypodermis:  
The hypodermis is not part of the skin, the deeper subcutaneous tissue (hypodermis) is made of 
fat and connective tissue. It’s purpose is to attach the skin to underlying bone and muscle as well 
as supplying it with blood vessels and nerves. It consists of looseconnective tissue and elastin
17
.  
COMPONENTS OF A NEEDLE FREE INJECTION DEVICE 
Devices may vary in design depending upon the drug for which they are used. 
1. Injection device 
  
 
It consists of a drug chamber and made up of plastic. Sterility is maintained throughout the 
device
18
.  
2. Nozzle 
The nozzle serves as passage for the drug. It has an orifice through whichthe drug enters skin 
after injection. The diameter of orifice typically is 100 μm. The nozzle fires drug particles at a 
typical speed of 100 m/s with a depth of 2 mm. Thus this injection is painless; the patient feels 
tap of gas on the skin which is like flicking finger against the skin
19
. 
3. Pressure source:  
The pressure source can be a mechanical method, stores energy in a spring and is released by 
pushing a plunger to provide the necessary pressure. It is important for delivering a drug 
forcefully into the systemic circulation via the skin. The most popular gasesused in devices are 
carbon dioxide or nitrogen
20
. 
MECHANISM 
The mechanism generates force by using compressed gas (such as carbon dioxide or nitrogen) to 
propel the drug through an orifice at a very high speed. While administration of drug occurs 
through the device, an ultra-fine stream of fluid penetrates through the skinlayers which deliver 
the drug very quickly into the systemic circulation
21
. The total time required to deliver an 
injection is less than 1/3 of a second and occurs in three stages: 
Stage 1- the peak pressure phase, optimal pressure used to penetrate the skin (< 0.025 sec). 
 Stage 2- the delivery or dispersion phase (~ 0.2 sec). 
Stage  3- the drop-off phase (< 0.05 sec).  
This pressure profile is consistent with each administration of vaccine ensuring each animal is 
vaccinated at the proper tissue depth. The needle-free injection technology improves the 
dispersion of medication throughout the tissue
22
. As the fluid stream forces it’s way through the 
tissue, it follows the path of least resistance, resulting in a widelydispersed, spider-web-like 
distribution of the medication
23
. 
TYPES OF NEEDLE FREE INJECTION SYSTEMS  
1. Powder injections 
These consist of a solid drug content filled in chamber and a nozzle for firing drug 
particles into the skin by utilizing compressed gas as the power source. A small volume of 
material, shot through the skin as drug, is in powder form instead of liquid form, hence injection 
is painless. The injection has a few microns thick diaphragm on either side of the chamber to 
cover the drug chamber.    
The sustained release effect or drug performance can be achieved by using bio erodible carriers, 
slowly dissolving excipients specific, less soluble salts or dissolution aids.Protein drugs are very 
potent, and suitable for powder needle free injection systems
24
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Figure 2: Mechanism of a powder injection  
2. Liquid injections 
The basic principle of this injection is generation of high enough pressure by a fluid in intimate 
contact with the skin, to deliver liquid by punching a hole into the skin.These systems use gas or 
spring, pistons, drug loaded compartments and nozzles having orifice size of about 150 to 300 
μm25.  
 
Figure 3: Mechanism of a liquid injection 
3. Depot or projectile injections 
These are designed for administration of a drug into muscles. Theycreate a store of drug 
into muscles that is released continuously over a desired time period
26
. 
 
Types of injections  
The needleless injections are mainly categorized into three types on the basis of the power source 
used in it.  
(1) Spring loaded injector- The spring loaded injector uses a spring mechanism which is drawn 
back to push the drug into the underlying tissue where the drug dissolves and is released into the 
blood stream. The activated spring load must be redrawn manually for thenext administration. 
Examples includes Dermojet®, Medi-jector®
27
. 
(2) Battery powered injector—Use of electricity as source of energy. It consists of a small 
rechargeable battery pack to retract the dosing device. The dosing device has an electric piston 
which is automatically redrawn after dosing. It is used for subcutaneous, intramuscular or 
transdermal delivery of drug. Examples include intradermal application ofliquids (IDAL) ®-
Intervet, Boxmeer
28
. 
(3) Gas powered injector- It is typically made of three components.  This system consists of an 
air/gas cartridge which is attached to the gun through a tubing system that delivers power to the 
piston after trigger actuation; it releases the piston and creates jet stream of drug. It is suitable for 
subcutaneous, intramuscular or transdermal use. Examples include Needle-Free-Felton, 
Biojector®, Pulse®, Lenexa, Ks. Agro-Jet®/Med-Jet®- Mit
29
. 
 
RECENT NEEDLE-FREE INJECTION TECHNOLOGIES 
1. Serojet 
The device is designed for delivering Serostim recombinant human growth hormone 
administered subcutaneously. The Serojet device is tailored from Vitajet technology. This is used 
for treatment of HIV associated wasting in adults and was approved byFDA in March 2001 for 
marketing
30
. 
  
 
 
Figure 4: Serojet 
2. Iject 
It is a product of the Bioject Company as a second generation gas powdered 
injection system. The Iject is a pre-filled single-use disposable injectiondevice configured to 
administer 0.5 to 1.00 ml subcutaneous or intramuscular injections. 
The device is initiated by rotating the trigger sleeve 180 degrees. By advancing the trigger 
sleeve, the injection is administered, where the nozzle is placed against the injection site
31
. 
 
Figure 5: Iject 
3. Injex  
Injex system offers administration of local anesthesia. It consists of aninjection ampoule having 
orifice of 0.18 mm. From this orifice, the drug is fired under dosed pressure into the submucosa. 
The ampoule must be placed on the attached gingiva at an angle of 90° directly above the tooth 
to be anaesthetized. The local anesthetic volume that can be administered is about 0.3 mL
32
. 
 
Figure 6: Injex 
4. Bioject®Zetajet  
It consists of two components, the portable injector and an auto disablingdisposable syringe. It is 
intended to deliver vaccines and injectable medications either subcutaneously or intramuscularly 
and is indicated for both professional use and home use for patients who self-inject. The syringe 
assembly has a unique “auto-disable” feature that prevents re-use of the syringe33. 
 
Figure 7: BioJect 
  
 
6. Cool click: 
Bioject developed it for delivering Saizen recombinant human growthhormone. In some 
children, naturally occurring growth hormone is absent or is produced in inadequate amounts. In 
these cases, Saizen or growth hormone replacement must be injected to maintain normal 
growth
34
. 
 
Figure 8: Cool  click     
7. Vitajet  
It received FDA approval for marketing in 1996. It consists of disposablenozzles which are 
replaceable once in week and used for delivery of insulin subcutaneously
35
.  
 
Figure 9: Vitajet 
8. Mhi-500 
This device is used for subcutaneous administration of insulin. The system wasapproved by FDA 
in 1996 and for sale throughout Europe. The device creates a fine jet of insulin through the 
nozzle penetrating skin tissues of the subcutaneous layer
36
. 
9. Madajet 
It is commonly used in dentistry. It works by using pneumatic pressure to discharge local 
anesthetic. This stream makes a wheel of about 5 to 6 mm in diameter at thebase of injection. 
The device injects a volume of 0.1 cc per injection intradermally
37
. 
APPLICATIONS 
The following are the drugs which are widely used with this technology. 
1. Insulin, which is to be administered several times during the day is consideredto be the best 
candidate for needleless delivery
38
. 
2. Lidocaine hydrochloride, a local anesthetic is suitable to be delivered needle free. 
3. Heparin (an anticoagulant), erythropoietin, lidocaine hydrochloride (a local anesthetic) and 
various vaccines can be administered through needleless injection
39
. 
This technology has been tried with several newer drugs to delivery them in a patient compliant 
way and has been successful in most cases. 
CONCLUSION  
In the developing world, there are major challenges of disease transmissionthrough re-use of 
needles. There appears to be tremendous opportunity for needle-free technology in 
pharmaceutical industry. Needle Free Injectors are easier to use, more efficient, more reliable, 
  
 
much safer and have no disposal problems. Additional benefits include veryfast injection as 
compared with conventional needles. 
Acceptance by patients, continuing developments and lowering costs all make needle free 
systems the best method for vaccinations.  Not only it can benefit in increasing product sales, it 
has the added potential to increase compliance with dosage regimens and improved results. 
Some of the applications expected to be key to the success of needle-free technologies include 
vaccines, biotechnology drugs - protein and peptide delivery, gene delivery, and insulin.  
There is a need to trained and educate the workers about this technology. Start-up and training 
costs may also affect the interest in this technology for some producers. Thefuture of needle-free 
injection systems looks bright, with a steady growth due to increasing demand for prevention of 
needle stick injuries and painless delivery of medication. 
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